BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 26109265)

  • 1. Detection and role of minimal disseminated disease in children with lymphoblastic lymphoma: The AIEOP experience.
    Mussolin L; Buldini B; Lovisa F; Carraro E; Disarò S; Lo Nigro L; d'Amore ES; Pillon M; Basso G
    Pediatr Blood Cancer; 2015 Nov; 62(11):1906-13. PubMed ID: 26109265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymphoblastic lymphoma.
    Cortelazzo S; Ponzoni M; Ferreri AJ; Hoelzer D
    Crit Rev Oncol Hematol; 2011 Sep; 79(3):330-43. PubMed ID: 21273093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone marrow minimal disseminated disease (MDD) and minimal residual disease (MRD) in childhood T-cell lymphoblastic lymphoma stage III, detected by flow cytometry (FC) and real-time quantitative polymerase chain reaction (RQ-PCR).
    Stark B; Avigad S; Luria D; Manor S; Reshef-Ronen T; Avrahami G; Yaniv I
    Pediatr Blood Cancer; 2009 Jan; 52(1):20-5. PubMed ID: 19006253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL.
    van der Velden VH; Jacobs DC; Wijkhuijs AJ; Comans-Bitter WM; Willemse MJ; Hählen K; Kamps WA; van Wering ER; van Dongen JJ
    Leukemia; 2002 Aug; 16(8):1432-6. PubMed ID: 12145681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Lymphoblastic lymphoma and acute lymphoblastic leukemia: a clinicopathologic, immunophenotypic and prognostic study in 153 Chinese patients].
    Pan Y; Li GD; Liu WP; Zhang WY; Tang Y; Li FY
    Zhonghua Bing Li Xue Za Zhi; 2009 Dec; 38(12):810-5. PubMed ID: 20193455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: A French multicenter study.
    Fossat C; Roussel M; Arnoux I; Asnafi V; Brouzes C; Garnache-Ottou F; Jacob MC; Kuhlein E; Macintyre-Davi E; Plesa A; Robillard N; Tkaczuk J; Ifrah N; Dombret H; Béné MC; Baruchel A; Garand R;
    Cytometry B Clin Cytom; 2015 Jan; 88(1):21-9. PubMed ID: 25363877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical relevance of CD10 expression in childhood ALL. The Italian Association for Pediatric Hematology and Oncology (AIEOP).
    Consolini R; Legitimo A; Rondelli R; Guguelmi C; Barisone E; Lippi A; Cantù-Rajnoldi A; Aricò M; Conter V; Cocito MG; Putti MC; Pession A; Masera G; Biondi A; Basso G
    Haematologica; 1998 Nov; 83(11):967-73. PubMed ID: 9864914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphoblastic lymphoma in childhood and adolescence.
    Schmidt E; Burkhardt B
    Pediatr Hematol Oncol; 2013 Sep; 30(6):484-508. PubMed ID: 23621872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results of treatment of lymphoblastic lymphoma at the children cancer hospital Egypt - A single center experience.
    Rahman Sayed HA; Sedky M; Hamoda A; Kinaaie NE; Wakeel ME; Hesham D
    J Egypt Natl Canc Inst; 2016 Sep; 28(3):175-81. PubMed ID: 27339800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical features and prognosis of children with lymphoblastic lymphoma].
    Jin L; Zhang R; Huang S; Yang J; Duan YL; Zhang YH
    Zhonghua Zhong Liu Za Zhi; 2012 Feb; 34(2):138-42. PubMed ID: 22780934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Impact of Intensified Maintenance Therapy on Children With Advanced Lymphoblastic Lymphoma: A Report From the Japanese Pediatric Leukemia/Lymphoma Study Group ALB-NHL03 Study.
    Sunami S; Sekimizu M; Takimoto T; Mori T; Mitsui T; Fukano R; Saito AM; Watanabe T; Ohshima K; Fujimoto J; Nakazawa A; Kobayashi R; Horibe K; Tsurusawa M
    Pediatr Blood Cancer; 2016 Mar; 63(3):451-7. PubMed ID: 26585702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemia.
    Björklund E; Mazur J; Söderhäll S; Porwit-MacDonald A
    Leukemia; 2003 Jan; 17(1):138-48. PubMed ID: 12529671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Role of Minimal Disseminated Disease and
    Lovisa F; Gallingani I; Varotto E; Pasin C; Carraro E; Michielotto B; Garbin A; Damanti CC; Pizzi M; d'Amore ESG; Piglione M; Muggeo P; Buffardi S; Vinti L; Folsi VM; Onofrillo D; Biffi A; Buldini B; Pillon M; Mussolin L
    Diagnostics (Basel); 2021 Sep; 11(9):. PubMed ID: 34573936
    [No Abstract]   [Full Text] [Related]  

  • 14. Flow-cytometric monitoring of disease-associated expression of 9-O-acetylated sialoglycoproteins in combination with known CD antigens, as an index for MRD in children with acute lymphoblastic leukaemia: a two-year longitudinal follow-up study.
    Chowdhury S; Bandyopadhyay S; Mandal C; Chandra S; Mandal C
    BMC Cancer; 2008 Feb; 8():40. PubMed ID: 18241334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Major impact of an early bone marrow checkpoint (day 21) for minimal residual disease in flow cytometry in childhood acute lymphoblastic leukemia.
    Eveillard M; Robillard N; Arnoux I; Garand R; Rialland F; Thomas C; Strullu M; Michel G; Béné MC; Fossat C; Loosveld M
    Hematol Oncol; 2017 Jun; 35(2):237-243. PubMed ID: 26449287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective monitoring of minimal residual disease during the course of chemotherapy in patients with acute lymphoblastic leukemia, and detection of contaminating tumor cells in peripheral blood stem cells for autotransplantation.
    Seriu T; Yokota S; Nakao M; Misawa S; Takaue Y; Koizumi S; Kawai S; Fujimoto T
    Leukemia; 1995 Apr; 9(4):615-23. PubMed ID: 7723394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - long-term results of trial ALL-REZ BFM P95/96.
    Eckert C; von Stackelberg A; Seeger K; Groeneveld TW; Peters C; Klingebiel T; Borkhardt A; Schrappe M; Escherich G; Henze G
    Eur J Cancer; 2013 Apr; 49(6):1346-55. PubMed ID: 23265714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Precursor B- or T-lymphoblastic lymphoma presenting with cutaneous involvement: a series of 13 cases including 7 cases of cutaneous T-lymphoblastic lymphoma.
    Lee WJ; Moon HR; Won CH; Chang SE; Choi JH; Moon KC; Lee MW
    J Am Acad Dermatol; 2014 Feb; 70(2):318-25. PubMed ID: 24314877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of CD58 in normal, regenerating and leukemic bone marrow B cells: implications for the detection of minimal residual disease in acute lymphocytic leukemia.
    Veltroni M; De Zen L; Sanzari MC; Maglia O; Dworzak MN; Ratei R; Biondi A; Basso G; Gaipa G;
    Haematologica; 2003 Nov; 88(11):1245-52. PubMed ID: 14607753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relapsed or Refractory Lymphoblastic Lymphoma in Children: Results and Analysis of 23 Patients in the EORTC 58951 and the LMT96 Protocols.
    Michaux K; Bergeron C; Gandemer V; Mechinaud F; Uyttebroeck A; Bertrand Y;
    Pediatr Blood Cancer; 2016 Jul; 63(7):1214-21. PubMed ID: 27037853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.